Biotech News
Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial
ir.genenta.com2026-05-06 15:06 EST
Company Announces Approximately $30 Million in Cash and Short-Term Investments Following Its October 27th Registered Direct Offering MILAN, Italy and NEW YORK , Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform